Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.57 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985985 | 0.86 | MAPT (0.58) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL27759009 | 0.85 | LMNA (0.76) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL4286068 | 0.84 | MAPT (0.94) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL4517587 | 0.83 | LMNA (1.00) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL30739929 | 0.83 | LMNA (1.00) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL27946687 | 0.82 | KMT2A (0.64) | LMNAKCNK3MEN1KMT2AHTT | |
| SCHEMBL2888312 | 0.81 | NPC1 (0.53) | MAPTP2RX1HTTRAB9ATSHR | |
| SCHEMBL5227631 | 0.80 | P2RX1 (1.00) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL3709728 | 0.79 | MEN1 (0.64) | LMNAMAPTKCNK3P2RX1PTGS1 | |
| SCHEMBL874391 | 0.79 | KCNQ3 (0.55) | LMNAMAPTKCNK3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105916850-A | Substituted dialkyl(oxido)- Lambda 4-sulfanylidene nicotinamide derivatives as kinase inhibitors | 阿勒根公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-103842332-A | Cyclopropaneamine compound | TAKAEDA CHEMICAL IND LTD | 2014-06-04 | — | — | CN | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | LMNA 4314/4885MAPT 4853/4885KCNK3 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.